Is Johnson & Johnson Stock Halal?

Johnson & Johnson generated $94.19 billion in total revenue in fiscal 2025, split primarily between two segments: Innovative Medicine (pharmaceuticals covering oncology, immunology, neuroscience, and other therapeutic areas) and MedTech (surgical devices, orthopedics, vision care, and cardiovascular products). Following the 2023 spinoff of Kenvue, its former consumer health division that made Tylenol, Band-Aid, and Listerine, Johnson & Johnson is now a pure-play pharmaceutical and medical device company. Developing and selling medicines and medical devices is core, permissible commerce that treats illness and saves lives, and Johnson & Johnson carries no exposure to alcohol, tobacco, gambling, or conventional banking as a business line. The company's revenue is diversified across dozens of drugs and device categories, none of which introduces a compliance concern on its own.

Johnson & Johnson's non-permissible income is limited to $1.056 billion in interest income earned on the company's cash, cash equivalents, and marketable securities, a routine feature for a company of this scale that maintains substantial liquidity for research and development spending, acquisitions, and litigation reserves. Johnson & Johnson has faced significant talc-related litigation liabilities in recent years, and the interest income figure reflects returns on the cash balances the company holds partly in anticipation of these obligations. There are no other disclosed non-permissible revenue sources: no consumer alcohol or tobacco products, no gambling operations, and no lending business. This makes Johnson & Johnson's compliance profile simple to assess relative to conglomerates with more diversified, harder-to-screen revenue streams.

At 1.12% impure revenue, Johnson & Johnson sits 3.88 percentage points below the 5% AAOIFI compliance threshold. Johnson & Johnson's interest income would need to nearly quadruple relative to total revenue for the ratio to approach the compliance boundary, an unlikely scenario absent a major shift in the company's cash management strategy or a large one-time asset sale. Johnson & Johnson's financial ratios also clear AAOIFI's screens comfortably: total debt of approximately $47.9 billion as of the end of fiscal 2025 represents roughly 8% of the company's 2026 market capitalization, well under the 30 to 33% ceiling AAOIFI-aligned screens typically apply to debt and interest-bearing securities relative to market value. This combination of low revenue impurity and conservative balance sheet ratios is why Musaffa, Zoya, and other major screeners consistently rate Johnson & Johnson compliant.

Johnson & Johnson is suitable for Shariah-conscious investors seeking healthcare sector exposure. The purification obligation is modest, $1.12 for every $100 invested, reflecting a revenue base built entirely on pharmaceuticals and medical technology with only routine interest income as an impurity. Investors should be aware that Johnson & Johnson carries elevated litigation risk related to historical talc products, a legal and financial consideration distinct from Shariah screening, but one worth factoring into investment decisions generally. On the specific question of religious compliance, Johnson & Johnson screens cleanly, and investors can proceed with confidence, purifying the small annual amount attributable to interest income.